|Videos|September 27, 2022
Available Treatment Options for Somatostatin Analog-Refractory Carcinoid Syndrome
A medical oncologist reviews the currently available, NCCN-approved treatments for somatostatin analog-refractory carcinoid syndrome.
Advertisement
Episodes in this series
Advertisement
Related to this article
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Paolo Tarantino, MD, PhD, discusses key data with ADCs in breast cancer that were presented at ASCO 2026.
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
Andrew H. Ko, MD, discusses how TTFields works and data that supported the FDA approval of Optune Pax for patients with pancreatic cancer.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in Beat acute myeloid leukemia.
A Mayo Clinic study found that a new immunotherapy helped patients with aggressive bladder cancer keep their bladder instead of having it removed.
A supplemental new drug application for selinexor plus ruxolitinib for myelofibrosis in August 2026 under the accelerated approval pathway.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mHSPC
2
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
3
Rethinking Lung Cancer Screening Paradigms
4
OncLive Weekly News Quiz (7/31/2026): Did You Catch This Week's Melanoma, Head and Neck, and Gastric Cancer Updates?
5